APM
NTLA icon

Avidity Partners Management’s Intellia Therapeutics NTLA Stock Holding History

Avidity Partners Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.97M Buy
+150,000
New +$1.91M 0.21% 34
2025
Q3 		– Sell
-232,000
Closed -$2.18M – 56
2025
Q2 		$2.18M Buy
+232,000
New +$1.91M 0.43% 48
2024
Q3 		– Sell
-170,000
Closed -$3.8M – 95
2024
Q2 		$3.8M Buy
+170,000
New +$4.05M 0.16% 75
2024
Q1 		– Sell
-447,434
Closed -$13.6M – 101
2023
Q4 		$13.6M Buy
447,434
+68,334
+18% +$1.96M 0.5% 55
2023
Q3 		$12M Sell
379,100
-16,755
-4% -$650K 0.48% 61
2023
Q2 		$16.1M Sell
395,855
-21,145
-5% -$857K 0.56% 60
2023
Q1 		$15.5M Sell
417,000
-221,200
-35% -$8.68M 0.52% 59
2022
Q4 		$22.3M Sell
638,200
-360,900
-36% -$17.2M 0.48% 48
2022
Q3 		$55.9M Sell
999,100
-126,094
-11% -$7.82M 1.14% 32
2022
Q2 		$58.2M Buy
1,125,194
+735,119
+188% +$37.3M 1.34% 25
2022
Q1 		$28.3M Buy
+390,075
New +$33M 0.59% 45
2021
Q4 		– Sell
-251,000
Closed -$33.7M – 107
2021
Q3 		$33.7M Sell
251,000
-129,000
-34% -$19.5M 0.75% 45
2021
Q2 		$61.5M Buy
+380,000
New +$29.6M 1.66% 21
2021
Q1 		– Sell
-303,000
Closed -$16.5M – 114
2020
Q4 		$16.5M Buy
+303,000
New +$11M 0.54% 54
2020
Q3 		– Sell
-418,178
Closed -$8.79M – 81
2020
Q2 		$8.79M Buy
+418,178
New +$7.1M 0.56% 47

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Avidity Partners Management's NTLA Position: Q1 2026 in Review

Avidity Partners Management opened a new position in Intellia Therapeutics (NTLA) in Q1 2026: 150,000 shares worth $1.97M. The stake represents 0.21% of the portfolio and ranks #34 among its holdings. This is a return to the name: Avidity Partners Management previously reported a position in NTLA as recently as Q2 2025.

Avidity Partners Management first reported a position in NTLA in Q2 2020 and has held it in 15 quarters since. The position peaked at $61.5M in Q2 2021. 302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Avidity Partners Management held 150,000 shares of Intellia Therapeutics worth $1.97M as of Q1 2026.
  • Intellia Therapeutics was a new Avidity Partners Management position in Q1 2026.
  • Intellia Therapeutics made up 0.21% of Avidity Partners Management's portfolio in Q1 2026, its #34 holding.
  • Avidity Partners Management first reported a position in Intellia Therapeutics in Q2 2020 and has held it in 15 quarters since.
  • Avidity Partners Management's Intellia Therapeutics position peaked at $61.5M in Q2 2021.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Avidity Partners Management's 13F filing for Q1 2026, filed 13 May 2026.